Similarity of fractionated versus single dose(s) of gemtuzumab ozogamicin as part of the MIDAM salvage regimen in relapsed/refractory acute myeloid leukemia patients-Reference-Cited by-同舟云学术

Similarity of fractionated versus single dose(s) of gemtuzumab ozogamicin as part of the MIDAM salvage regimen in relapsed/refractory acute myeloid leukemia patients

Published:2016-07 Issue:3 Volume:53 Page:216-217
ISSN:0037-1963
Container-title:Seminars in Hematology
language:en
Short-container-title:Seminars in Hematology

Author:

Peterlin Pierre,Guillaume Thierry,Delaunay Jacques,Mohty Mohamad,Garnier Alice,Mahe Beatrice,Dubruille Viviane,Blin Nicolas,Voldoire Maud,Touzeau Cyrille,Chauvin Cecile,Gastinne Thomas,Béné Marie C,Le Gouill Steven,Moreau Philippe,Chevallier Patrice

Publisher

Elsevier BV

Subject

Hematology

Reference10 articles.

1. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence;Larson;Cancer,2005

2. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia;Chevallier;J Clin Oncol,2008

3. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study;Castaigne;Lancet,2012

4. Venoocclusive disease of the liver following bone marrow transplantation;Jones;Transplantation,1987

5. Gemtuzumab ozogamicin in combination with intensive chemotherapy in relapsed or refractory acute myeloid leukemia;Chantepie;Leuk Lymphoma,2015

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review;Annals of Hematology;2018-04-21

2. Fractionated Dosing Improves Preclinical Therapeutic Index of Pyrrolobenzodiazepine-Containing Antibody Drug Conjugates;Clinical Cancer Research;2017-06-19

3. Clinicopathological characteristics and prognostic value of cancer stem cell marker CD133 in breast cancer: a meta-analysis;OncoTargets and Therapy;2017-02